"moduleName": "announcement",
  "moduleDescriptor": {
    "templatePath": "/Layouts/Announcement/list.html",
    "parameters": "filter=\"all\",collection=\"output\",template=\"\"",
    "apiEndpoint": "/api/v3/announcement",
    "objectType": 7,
    "objectId": -1,
    "adminUrl": "/Admin/Announcements_Details.aspx?AnnouncementID=-1"
  "editableFieldTypes": {
    "body": "Html",
    "id": "Id",
    "subject": "Text",
    "fromDate": "Date",
    "toDate": "Date",
    "releaseDate": "Date",
    "expiryDate": "Date",
    "lastUpdateDate": "Date"
  "items": [
      "body": "



Network Immunology Inc. Chief Scientist, Dr. Reginald Gorczynski being interviewed by co-founder, George Hoffmann.


\n \n

", "id": 94733, "url": "/announcements/interview-with-dr-reginald-gorczynski", "subject": "Interview with Dr. Reginald Gorczynski", "fromDate": "2017-10-06T00:00:00", "fromDate_raw": "2017-10-06T17:00:00", "toDate": "2017-12-06T00:00:00", "toDate_raw": "2017-12-06T18:00:00", "releaseDate": "2017-12-21T00:00:00", "releaseDate_raw": "2017-12-21T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2019-03-04T14:59:32.147", "lastUpdateDate_raw": "2019-03-05T08:59:32.147", "counter": 1 }, { "body": "



A paper has been published by Reginald Gorczynski and Geoffrey Hoffmann entitled:\n


\"Toward a New Kind of Vaccine: A Logical Extension of the Symmetrical Immune Network Theory\"\n


The paper can be found via this link: www.i-jmr.org/2017/2/e8/\n


This paper provides much of the data that underlies Network Immunology’s proprietary platform technology and products.



", "id": 94732, "url": "/announcements/experimental-results-published-by-dr-gorczynski-and-dr-hoffmann", "subject": "Paper published by Dr. Gorczynski and Dr. Hoffmann", "fromDate": "2017-07-05T00:00:00", "fromDate_raw": "2017-07-05T17:00:00", "toDate": "2017-07-05T00:00:00", "toDate_raw": "2017-07-05T17:00:00", "releaseDate": "2017-12-21T00:00:00", "releaseDate_raw": "2017-12-21T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2017-12-21T16:09:18.37", "lastUpdateDate_raw": "2017-12-22T10:09:18.37", "counter": 2 }, { "body": "


\n \n
", "id": 76725, "url": "/announcements/chief-scientist-dr-geoff", "subject": "Interview with Dr. Geoffrey Hoffmann", "fromDate": "2015-05-27T00:00:00", "fromDate_raw": "2015-05-27T17:00:00", "toDate": "2015-05-27T00:00:00", "toDate_raw": "2015-05-27T17:00:00", "releaseDate": "2015-05-27T00:00:00", "releaseDate_raw": "2015-05-27T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2017-12-21T18:07:01.173", "lastUpdateDate_raw": "2017-12-22T12:07:01.173", "counter": 3 }, { "body": "

CEO George Hoffman discusses Network Immunology's latest research breakthrough in organ transplantation.

", "id": 76420, "url": "/announcements/harpreet-singh-show-interview-organ-transplantation", "subject": "Interview on Organ Transplantation, Harpreet Singh Show", "fromDate": "2015-05-04T00:00:00", "fromDate_raw": "2015-05-04T17:00:00", "toDate": "2015-05-04T00:00:00", "toDate_raw": "2015-05-04T17:00:00", "releaseDate": "2015-05-04T00:00:00", "releaseDate_raw": "2015-05-04T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2015-05-04T12:53:45.087", "lastUpdateDate_raw": "2015-05-05T05:53:45.087", "counter": 4 }, { "body": "

Toronto, ON: Network Immunology has received breakthrough data for its platform Co-selection Technology™ that has potential applications to transplantation, autoimmunity and other degenerative diseases. The pilot study, conducted at the University of Toronto, involved modifying one group of mice' immune systems, to be fundamentally similar to that of another group of mice. This study involved administration of NI’s patented immunotherapeutic antibody. A subtle modification of the immune system caused approximately 100% increase in skin graft survival time, without the use of immunosuppressant drugs.\n


Dr. Geoffrey Hoffmann, Chief Scientist spoke on the recent results. \"In light of this data, we expect it will be possible to change the immune system of a person who is susceptible to a given degenerative disease, to be similar to the immune system of someone who is resistant to the development of that disease. Moreover, the data fits perfectly within the context of the company's unique way of understanding the adaptive immune system, that is, within the immune network framework. This data means we are on track to solving fundamental immunological problems including not only transplant rejection, but also autoimmunity and other degenerative diseases.\"\n


Network Immunology is actively seeking financing and collaborative partnerships in order to further develop its technologies.

\n", "id": 74871, "url": "/announcements/network-immunology-releases-breakthrough-data-from-organ-transplantation-study", "subject": "Network Immunology Releases Breakthrough Data from Organ Transplantation Study", "fromDate": "2014-11-26T00:00:00", "fromDate_raw": "2014-11-26T18:00:00", "toDate": "2014-12-27T00:00:00", "toDate_raw": "2014-12-27T18:00:00", "releaseDate": "2014-11-26T00:00:00", "releaseDate_raw": "2014-11-26T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2015-05-04T11:55:02.953", "lastUpdateDate_raw": "2015-05-05T04:55:02.953", "counter": 5 }, { "body": "

Vancouver, BC: Network Immunology has completed a financing in partnership with one of the largest wealth management firms in Canada. “We are delighted with this development, as it is a major milestone that will allow the Company to thrive and advance its research and development programs\", says George Hoffmann, President and CEO.



\n", "id": 75212, "url": "/announcements/network-immunology-inc-completes-financing-1", "subject": "Network Immunology Completes Private Equity Financing", "fromDate": "2014-07-29T00:00:00", "fromDate_raw": "2014-07-29T17:00:00", "toDate": "2014-07-30T00:00:00", "toDate_raw": "2014-07-30T17:00:00", "releaseDate": "2015-01-25T00:00:00", "releaseDate_raw": "2015-01-25T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2015-05-04T11:55:26.017", "lastUpdateDate_raw": "2015-05-05T04:55:26.017", "counter": 6 }, { "body": "

Atlanta, GA: Network Immunology reports highly encouraging results have been observed with respect to its HIV therapeutic technology, TheraNet™. In the company’s first study involving TheraNet™ caused an average 86% reduction in viral load in two of four SIV infected macaque monkeys.  TheraNet™ is an entirely new method of HIV therapy, based on the immune network framework. \"This therapeutic is entirely different from the existing mainstream anti-retroviral drugs which cause very substantial side-effects.  And, because it works with the system, we expect very minimal, and even potentially no side-effects\", says George Hoffmann, President and CEO.

\n", "id": 74869, "url": "/announcements/novel-hiv-therapeutic-theranet", "subject": "Network Immunology Announces Data for Entirely Novel Method of HIV Therapy: TheraNet™", "fromDate": "2014-03-19T00:00:00", "fromDate_raw": "2014-03-19T17:00:00", "toDate": "2014-03-19T00:00:00", "toDate_raw": "2014-03-19T17:00:00", "releaseDate": "2014-03-19T00:00:00", "releaseDate_raw": "2014-03-19T17:00:00", "expiryDate": "2099-01-01T00:00:00", "expiryDate_raw": "2099-01-01T18:00:00", "lastUpdateDate": "2015-05-04T11:55:45.653", "lastUpdateDate_raw": "2015-05-05T04:55:45.653", "counter": 7 }, { "body": "

Network Immunology, a preclinical stage biotech company focused on novel treatments to prevent and treat automimmune conditions and cancer, adds expert immunologists in the field of immune network science to its team.\nDr. Sybille Muller and Dr. Heinz Kohler, who discovered and rearched NetVac™ molecule, have been appointed to the Board of Directors and Scientific Advisory Board, respectively.

\r\n", "id": 74372, "url": "/announcements/dr-matthew-parsons-joins-network-immunologys-scientific-advisory-board", "subject": "Dr. Matthew Parsons Joins Network Immunology's Scientific Advisory Board", "fromDate": "2012-08-12T00:00:00", "fromDate_raw": "2012-08-12T17:00:00", "toDate": "2014-11-10T00:00:00", "toDate_raw": "2014-11-10T18:00:00", "releaseDate": "2012-08-12T00:00:00", "releaseDate_raw": "2012-08-12T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2014-11-18T17:26:17.05", "lastUpdateDate_raw": "2014-11-19T11:26:17.05", "counter": 8 }, { "body": "

Two experienced immunologists in the field of immune network science, Dr. Sybille Muller and Dr. Heinz Kohler, have joined Network Immunology.  Dr. Muller has been appointed to the Board of Directors, and Dr. Heinz Kohler has been appointed Chairman of the Scientific Advisory Board.  They discovered and researched the NetVac™ molecule that is a major component of the Network Immunology HIV vaccine.

\r\n", "id": 74373, "url": "/announcements/drs-muller-and-heinz", "subject": "Dr. Sybille Muller and Dr. Heinz Kohler join team at Network Immunology", "fromDate": "2012-08-10T00:00:00", "fromDate_raw": "2012-08-10T17:00:00", "toDate": "2014-08-10T00:00:00", "toDate_raw": "2014-08-10T17:00:00", "releaseDate": "2012-08-10T00:00:00", "releaseDate_raw": "2012-08-10T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2014-12-28T18:56:33.003", "lastUpdateDate_raw": "2014-12-29T12:56:33.003", "counter": 9 }, { "body": "

Network Immunology, a preclinical stage biotech company focused on novel treatments to prevent and treat automimmune conditions and cancer, announces a new monoclonal antibody-based technology.\nNetwork Immunology’s Chief Scientist, Geoffrey W. Hoffmann, has discovered a way to make a kind of antibody for humans that has been shown in studies with mice to be intimately associated with the suppression of the immune system. Network Immunology has filed a patent application for the use of this kind of antibody in the prevention and treatment of autoimmunity.

\r\n", "id": 74374, "url": "/announcements/network-immunology-announces-mab3", "subject": "Network Immunology Announces MAB3™", "fromDate": "2011-02-12T00:00:00", "fromDate_raw": "2011-02-12T18:00:00", "toDate": "2014-11-10T00:00:00", "toDate_raw": "2014-11-10T18:00:00", "releaseDate": "2011-02-12T00:00:00", "releaseDate_raw": "2011-02-12T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2014-12-30T12:28:36.473", "lastUpdateDate_raw": "2014-12-31T06:28:36.473", "counter": 10 }, { "body": "

Network Immunology, a preclinical stage biotech company focused on novel treatments to prevent and treat automimmune conditions and cancer, files patent for HIV and organ transplantation technologies.\nOn January 4th, 2011, Network Immunology Inc. filed provisional patent applications for it’s HIV vaccine and organ transplantation technologies. Both of these technologies have emerged from recent developments in Network Theory as applied to the immune system, and are closely related to each other at the level of the fundamental science. This was soon followed by a patent application for its MAB3 technology. On January 4th, 2012, the Company filed three Patent Convention Treaty applications, one for each of its technologies.\nNetwork Immunology Inc. is seeking private equity financing in order to develop these technologies as quickly as possible.

\r\n", "id": 74375, "url": "/announcements/network-immunology-inc-reports-filing-of-new-intellectual-property", "subject": "Network Immunology Inc. Reports Filing of New Intellectual Property ", "fromDate": "2011-01-10T00:00:00", "fromDate_raw": "2011-01-10T18:00:00", "toDate": "2014-11-10T00:00:00", "toDate_raw": "2014-11-10T18:00:00", "releaseDate": "2011-01-10T00:00:00", "releaseDate_raw": "2011-01-10T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2014-12-30T12:29:05.437", "lastUpdateDate_raw": "2014-12-31T06:29:05.437", "counter": 11 } ], "params": { "filter": "all", "collection": "output", "template": "" } }